Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts

1
OpportunityAnalyzer Respiratory Syncytial Virus
(RSV) - Opportunity Analysis and Forecasts to 2024
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Human respiratory syncytial virus (RSV) is an
  enveloped, single-stranded, negative-sense
  ribonucleic acid (RNA) pneumovirus belonging to
  the family of Paramyxoviridae. The virus was
  discovered in 1956, first as an isolate from a
  laboratory chimpanzee displaying symptoms of the
  common cold, and later from infants suffering
  from respiratory disease. RSV can cause upper
  respiratory tract infections (the common cold)
  and is the most important cause of lower
  respiratory tract infections, such as
  bronchiolitis and pneumonia, in infants. RSV is
  also an important cause of hospitalizations and
  deaths in elderly adults.
• Today, Medimmunes Synagis (palivizumab) is the
  only licensed intervention for the prevention of
  RSV in infants at a high risk of severe
  infection. This humanized, mouse monoclonal
  antibody (mAb) was first approval in 1998, and
  while it is an efficacious prophylactic
  intervention, its short 20-day half-life
  necessitates monthly dosing during the RSV
  season. Moreover, the high cost of Synagis limits
  its use to certain subgroups of infants who are
  at high risk of severe RSV infection, and it is
  not indicated for use in elderly adults, leaving
  a key population of high-risk individuals
  unprotected. Furthermore, due to the absence of
  effective RSV-specific antivirals, the treatment
  of RSV infections is largely restricted to a
  number of supportive treatment options. This
  projects the global RSV marketplace - which, for
  the purposes of this report, comprises the seven
  major pharmaceutical markets (7MM US, France,
  Germany, Italy, Spain, UK, Japan) - to experience
  unprecedented growth from 2014-2024, driven by
  the arrival of novel approaches to prevention and
  management of RSV.
• Scope
• - Overview of RSV infections, including
  epidemiology, etiology, pathophysiology,
  symptoms, diagnosis, and current management
  strategies.
• - Topline RSV market revenue from 2014-2024.
  Annual cost of therapy (ACOT) and major pipeline
  product sales in this forecast period are
  included.

3


Report Overview

• Key Findings
• The global RSV marketplace - which, for the
  purposes of this report, encompasses the sales of
  products for the prevention or treatment of RSV
  in the 7MM - was worth approximately 640m in
  2014. This projects the market to surpass 2.3bn
  in sales by 2024, at a compound annual growth
  rate (CAGR) of 29.9 from 2014-2024. The sales
  are projected to originate predominantly from the
  US (a 62 market share), followed distantly by
  the 5EU (a 29 market share).
• The anticipated arrival of novel prophylactic
  mAbs that boast improved dosing criteria compared
  with Synagis, led by MedImmunes MEDI8897, will
  be a principal driver of RSV market growth across
  the 7MM. The licensure of the first adult vaccine
  to offer protection against RSV, Novavaxs RSV-F
  Vaccine, will also stimulate rapid growth in a
  previously untapped segment of the marketplace.
• A persistent lack of patient and physician
  awareness of RSV in adult patients - specifically
  the infections substantial impact on morbidity
  and mortality in the elderly - will serve as a
  key impediment to market growth from 2014-2024.
• Strategic Focus Report _at_
• http//www.researchbeam.com/opportunityanalyzer-re
  spiratory-syncytial-virus-rsv-opportunity-analysis
  -and-forecasts-to-2024-market

4


Table of Contents
1 Table of Contents 10 1.1 List of Tables 15 1.2
List of Figures 18 2 Introduction 19 2.1 Catalyst
19 2.2 Related Reports 20 2.3 Upcoming Related
Reports 21 3 Disease Overview 22 3.1 Etiology and
Pathophysiology 22 3.2 Symptoms and Prognosis
28 3.3 Quality of Life 31 3.4 Disease Management
31 4 Epidemiology 40 4.1 Disease Background
40 4.2 Risk Factors and Comorbidities 41 4.3
Global Trends 434.4 Forecast Methodology
48 4.4.1 Sources Used 54 4.4.2 Sources Not Used
62 4.5 Epidemiological Forecast for RSV Infection
(2014-2024) 72 4.5.1 Risk Groups for Severe RSV
Infection in Children Less than Two Years
72 4.5.2 Preterm Births 78
5


Table of Contents
5 Current Treatment Options 87 5.1 Overview
87 5.2 Product Profiles - RSV Prophylactics
89 5.2.1 Synagis (palivizumab) 89 5.3 Product
Profiles - RSV Therapeutics 95 5.4 Other
Supportive Measures 101 6 Unmet Needs and
Opportunities 103 6.1 Overview 103 6.2 Effective
Therapeutic Interventions 105 6.2.1 Unmet Need
105 7 Research and Development Strategies 122 8
Pipeline Assessment 156 8.1 Overview 156 8.2
Promising Drugs in Clinical Development -
Prophylactic Agents 158 9 Pipeline Valuation
209 9.1 Overview 209 9.2 Clinical Benchmark of
Key Pipeline Products 209 9.2.1 Prophylactic
Agents 209 10 Appendix 234 10.1 Bibliography
234 10.2 Abbreviations 264 10.3 Methodology
270 10.4 Forecasting Methodology 270
6


Table of Figures
Figure 1 The RSV Virion 24 Figure 2 Life Cycle
of RSV 26 Figure 3 Case Flow Map for RSV
Prophylactic and Therapeutic Populations
54 Figure 4 Population Estimates and Births
Forecast for the US, Boys and Girls, 1997-2024
64 Figure 5 7MM, Children Born Preterm (lt37
Weeks GA) Surviving to Ages 0-2 Years, Boys and
Girls, N, 2014 and 2024 76 Figure 6 7MM,
Children at Risk for Severe RSV Infection, Boys
and Girls, Ages ?2 Years, N, 2014 77 Figure 7
7MM, Children at Risk for Severe RSV Infection,
Boys and Girls, Ages ?2 Years, N, 2024 78 Figure
8 Competitive Assessment of Key RSV Prophylactic
Agents, 2014-2024 215 Figure 9 Competitive
Assessment of Key RSV Therapeutic Agents,
2014-2024 217 Figure 10 Global Sales (m) for
RSV Therapeutics and Prophylactics by Region,
2014 and 2024 220 Figure 11 Global Sales (m)
for RSV Therapeutics and Prophylactics by Region,
2014-2024 221 Figure 12 Global Sales (m) for
RSV Therapeutics and Prophylactics by Product
Class, 2014-2024 222 Figure 13 Sales (m) for
RSV Prophylactics in the US, 2014-2024 226 Figure
14 Sales (m) for RSV Therapeutics in the US,
2024 227 Figure 15 Sales (m) for RSV
Prophylactics in the 5EU, 2014-2024 229 Figure
16 Sales (m) for RSV Therapeutics in the 5EU,
2024 230 Figure 17 Sales (m) for RSV
Prophylactics in Japan, 2014-2024 232 Figure 18
Sales (m) for RSV Therapeutics in Japan, 2024 233
7


Report Ordering
Report Name OpportunityAnalyzer Respiratory
Syncytial Virus (RSV) - Opportunity Analysis and
Forecasts to 2024.

Product Price
User Price
Single User US 8071
Site User US 18990
Global User US 28485
To View Sample or Purchase Report
8



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/opportunityanalyzer-re
spiratory-syncytial-virus-rsv-opportunity-analysis
-and-forecasts-to-2024-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com